These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 8449834)

  • 1. Meeting the challenges of beta-lactamases.
    Moellering RC
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():1-8. PubMed ID: 8449834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-lactamases and beta-lactamase inhibitors.
    Williams JD
    Int J Antimicrob Agents; 1999 Aug; 12 Suppl 1():S3-7; discussion S26-7. PubMed ID: 10526867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-lactamase-mediated resistance and opportunities for its control.
    Livermore DM
    J Antimicrob Chemother; 1998 Jun; 41 Suppl D():25-41. PubMed ID: 9688449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics.
    Chaïbi EB; Sirot D; Paul G; Labia R
    J Antimicrob Chemother; 1999 Apr; 43(4):447-58. PubMed ID: 10350372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition.
    Rotschafer JC; Ostergaard BE
    Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S15-22. PubMed ID: 7606585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    Surg Gynecol Obstet; 1991; 172 Suppl():11-6. PubMed ID: 2024221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability in the presence of widespread beta-lactamases. A prerequisite for the antibacterial activity of beta-lactam drugs.
    Schito GC; Pesce A; Debbia EA
    Drugs; 1994; 47 Suppl 3():1-8; discussion 8-9. PubMed ID: 7518761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases.
    Neu HC
    Am J Med; 1985 Nov; 79(5B):2-12. PubMed ID: 3907341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence of beta-lactamase-producing pathogens.
    Acar JF; Kitzis MD; Gutmann L
    APMIS Suppl; 1989; 5():2-8. PubMed ID: 2660867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in beta-lactamase research and their implications for the future.
    Bush K
    Rev Infect Dis; 1988; 10(4):681-90. PubMed ID: 3055169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tackling the Antibiotic Resistance Caused by Class A
    Eiamphungporn W; Schaduangrat N; Malik AA; Nantasenamat C
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Beta-lactamase inhibitors].
    Nishiya H; Kunii O
    Nihon Rinsho; 1991 Sep; 49(9):2046-51. PubMed ID: 1960873
    [No Abstract]   [Full Text] [Related]  

  • 17. Progress toward inhibitors of metallo-β-lactamases.
    McGeary RP; Tan DT; Schenk G
    Future Med Chem; 2017 May; 9(7):673-691. PubMed ID: 28504895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of beta-lactamase inhibitors.
    Jackson D
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):37S-39S. PubMed ID: 2041830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-lactam/β-lactamase inhibitor combinations: from then to now.
    Toussaint KA; Gallagher JC
    Ann Pharmacother; 2015 Jan; 49(1):86-98. PubMed ID: 25361682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-lactam resistance in anaerobic bacteria: a review.
    Hedberg M; Nord CE
    J Chemother; 1996 Feb; 8(1):3-16. PubMed ID: 8835102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.